

Zimmer complaint

Sydney, Australia Thursday, 24 June 2021, Next Science Limited (ASX:NXS) (Next Science / Company) advises that it has agreed to open negotiations with Zimmer, Inc (Zimmer), a global leader in orthopaedics and hip and knee replacement surgery, in relation to commercialisation and distribution rights to Next Science's XPerience™ No Rinse Antimicrobial Solution.

The negotiations follow the filing of a complaint by Zimmer in the United States District Court, Northern District of Indiana, alleging they have global commercial exclusivity rights over XPerience™. Next Science denies the allegations and if negotiations fail, intends to vigorously defend the complaint if and when it is served on Next Science. Zimmer has indicated that it will not serve the complaint on Next Science pending the outcome of the negotiations.

Approved and authorised for release by Next Science's Managing Director.

Further information:

Judith Mitchell

Managing Director, Next Science Limited

Phone: +61 2 9375 7989

Email: investorqueries@nextscience.com

Michael Brown

Pegasus Advisory Phone: +61 400 248 080

Email: mbrown@pegasusadvisory.com.au

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the Company's primary focus is on the development and continued commercialisation of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its Xbio technology. For further information visit: www.nextscience.com.